-
Mashup Score: 1Clinical validation of the tempus xT next-generation targeted oncology sequencing assay | Oncotarget - 2 year(s) ago
https://doi.org/10.18632/oncotarget.26797 Nike Beaubier, Robert Tell, Denise Lau, Jerod R. Parsons, Stephen Bush, Jason Perera, Shelly Sorrells, Timothy Baker, Alan Chang, Jackson Michuda, Catherine…
Source: www.oncotarget.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Clinical validation of the tempus xT next-generation targeted oncology sequencing assay | Oncotarget - 2 year(s) ago
https://doi.org/10.18632/oncotarget.26797 Nike Beaubier, Robert Tell, Denise Lau, Jerod R. Parsons, Stephen Bush, Jason Perera, Shelly Sorrells, Timothy Baker, Alan Chang, Jackson Michuda, Catherine…
Source: www.oncotarget.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay [Mar 22, 2019] Beaubier et al. @Oncotarget https://t.co/O3tqUKOVNr #PrecisionMedicine #oncopath #ImmunoOnc @TempusLabs https://t.co/pLNuIDeoBD
-
-
Mashup Score: 0Clinical validation of the tempus xT next-generation targeted oncology sequencing assay | Oncotarget - 2 year(s) ago
https://doi.org/10.18632/oncotarget.26797 Nike Beaubier, Robert Tell, Denise Lau, Jerod R. Parsons, Stephen Bush, Jason Perera, Shelly Sorrells, Timothy Baker, Alan Chang, Jackson Michuda, Catherine…
Source: www.oncotarget.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay [Mar 22, 2019] Beaubier et al. @Oncotarget https://t.co/O3tqUKOVNr #PrecisionMedicine #oncopath #ImmunoOnc @TempusLabs https://t.co/42d1W59L0L
-
-
Mashup Score: 2Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts - 2 year(s) ago
The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multiline…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts [Jul 11, 2018] @a_mangaonkar et al. Leukemia Research https://t.co/14DuYchKd1 #MDSsm #camoldx #oncopath https://t.co/Zuk6RURyv3
-
-
Mashup Score: 2Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes - 2 year(s) ago
PURPOSE Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication. METHODS We retrospectively enrolled 2,043 patients. Using Bayesian networks and Dirichlet processes, we combined mutations in 47 genes with cytogenetic abnormalities to identify genetic…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes [Feb 4, 2021] Bersanelli et al. @JCO_ASCO https://t.co/O3WjtfqNtp #MDSsm #oncopath #Hemepath #PrecisionMedicine
-
-
Mashup Score: 1Clinical validation of the tempus xT next-generation targeted oncology sequencing assay | Oncotarget - 2 year(s) ago
https://doi.org/10.18632/oncotarget.26797 Nike Beaubier, Robert Tell, Denise Lau, Jerod R. Parsons, Stephen Bush, Jason Perera, Shelly Sorrells, Timothy Baker, Alan Chang, Jackson Michuda, Catherine…
Source: www.oncotarget.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay [Mar 22, 2019] Beaubier et al. @Oncotarget https://t.co/O3tqUKOnXT #PrecisionMedicine #oncopath #ImmunoOnc @TempusLabs https://t.co/Shbj3il2tv
-
-
Mashup Score: 0Who’s In and Who’s Out? - ASH Clinical News - 2 year(s) ago
Who’s In and Who’s Out? – Feature Articles, Spotlight – ASH Clinical News
Source: ASH Clinical NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Are Clinical Trial Exclusion Criteria Too Strict? [Jan 12, 2016] @ASHClinicalNews https://t.co/i9cvglUaH7 #clinicaltrials #oncopath
-
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
DetailsCitationJ Clin Oncol 36, 2018 (suppl; abstr 9031)AuthorsNathan A. PennellCleveland Clinic, Cleveland, OHNathan A. Pennell, Alex Mutebi, Zheng-Yi Zhou, Marie Louise Ricculli, Wenxi Tang, Helen Wang, Annie Guerin, Tom Arnhart, Kenneth W. Culver, Gregory Alan OttersonOrganizationsCleveland Clinic, Cleveland, OH, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Analysis Group, New York,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Economic impact of NGS vs sequential single-gene testing modalities to detect genomic alterations in metastatic NSCLC using a decision analytic model - @n8pennell #ASCO18 Abstract 9031 https://t.co/YzkeKFNdCc #hpeonc #lcsm #PrecisionMedicine #camoldx #oncopath https://t.co/uGK0i6454F
-
-
Mashup Score: 0Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
HealthTree Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - Sweeney @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath @myelomacrowd https://t.co/J3H0jzK9AW
-
-
Mashup Score: 0Meeting Library | Meeting Library - 2 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
HealthTree Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - Sweeney @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath @myelomacrowd https://t.co/s9uTYyZNuR
-
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay [Mar 22, 2019] Beaubier et al. @Oncotarget https://t.co/O3tqUL5YPr #PrecisionMedicine #oncopath #ImmunoOnc @TempusLabs https://t.co/fZtwR9N1KG